Geode Capital Management LLC Sells 31,570 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Geode Capital Management LLC trimmed its position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 10.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 258,524 shares of the company’s stock after selling 31,570 shares during the period. Geode Capital Management LLC’s holdings in Vistagen Therapeutics were worth $778,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in VTGN. American Century Companies Inc. boosted its stake in Vistagen Therapeutics by 49.1% during the 2nd quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after purchasing an additional 9,984 shares during the period. Jane Street Group LLC acquired a new stake in shares of Vistagen Therapeutics in the third quarter worth $59,000. Blair William & Co. IL increased its position in Vistagen Therapeutics by 29.2% during the second quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after acquiring an additional 20,000 shares during the period. HighTower Advisors LLC acquired a new position in Vistagen Therapeutics during the 3rd quarter valued at $64,000. Finally, Valence8 US LP bought a new stake in Vistagen Therapeutics in the 3rd quarter valued at $103,000. 78.39% of the stock is currently owned by institutional investors.

Vistagen Therapeutics Stock Performance

NASDAQ:VTGN opened at $2.97 on Friday. The firm’s 50-day moving average is $2.76 and its 200-day moving average is $3.12. The company has a market cap of $82.69 million, a price-to-earnings ratio of -2.40 and a beta of 0.78. Vistagen Therapeutics, Inc. has a 52-week low of $2.22 and a 52-week high of $5.74.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.